The Medical Letter on Drugs and Therapeutics
Extended-Release Fluvoxamine (Luvox CR)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Fluvoxamine maleate, a selective serotonin reuptake inhibitor (SSRI) that has been available for many years in an immediate-release formulation (Luvox, and others) for treatment of obsessive-compulsive disorder (OCD) in children and adults, has now been approved by the FDA in an extended-release formulation (Luvox CR– Jazz Pharmaceuticals) for treatment of OCD and social anxiety disorder (SAD) in adults.

PHARMACOKINETICS — According to data in the package insert, Luvox CR has non-linear pharmacokinetics; the maximum plasma concentration (Cmax) with a 300-mg dose was 6.8 times higher than the Cmax with a 100-mg dose. The AUC and Cmax were 60% higher in women than in men.

EFFICACY — Fluvoxamine has not been shown to be more effective than any other SSRI for OCD (only fluoxetine, sertraline and paroxetine are also FDA-approved for this indication), and one ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Extended-Release Fluvoxamine (Luvox CR)
Article code: 1289b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian